rBet v1-FV

recombinant Bet v 1-FV allergen immunotherapy · Allergopharma GmbH & Co. KG

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for rBet v1-FV, covering 2013-03-04 to 2014-01-24. Get the full timeline:

Most recent: Clinical Trial Update: Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis [Phase 2]

See pricing